HOME >> BIOLOGY >> NEWS
Acorda Therapeutics receives L.W. Freeman Award for Scientific Research

Hawthorne, NY /Mesa, AZ November 13, 2002 - Acorda Therapeutics, a biotechnology company located in Hawthorne, NY, will receive the L.W. Freeman Award for Scientific Research tomorrow evening at the National Spinal Cord Injury Association (NSCIA) 2002 Annual Conference in Mesa, AZ.

This award is given annually for pioneering research on regeneration in spinal cord injury or disease and was established in memory of Dr. L. W. Freeman, who was one of the original members of the NSCIA Medical Advisory Committee. A scientist at Indiana University, Dr. Freeman was committed to research that advanced the knowledge of treatment for spinal cord injury. Dr. Freeman was a tireless researcher and teacher, and he served as a key advisor to the Association until his death in 1969.

Marcie Roth, Executive Director of the NSCIA, said, "The NSCIA recognizes the significant contribution that Acorda Therapeutics is making in scientific research that benefits the spinal cord injury community. Acorda's research platform encompasses a broad range of therapeutic targets ranging from regenerative therapies to therapies focused on improved function designed to improve the quality of life and overall health for persons living with a spinal cord injury."

Ron Cohen, M.D., Founder and CEO of Acorda Therapeutics, said, "Acorda is the first company to focus on the development of therapies to restore function in people with SCI. We are proud to be working with the NSCIA to achieve this and are honored to accept this award. Our lead product, Fampridine-SR, entered Phase 3 clinical trials for chronic SCI this year. This is the first time a therapy for improving function in chronic SCI has reached that milestone. Our relationship with the NSCIA continues to be an important catalyst in helping to move the research and education forward in SCI."

The awards ceremony will take place at The Sheraton Mesa Hotel and Convention Center at 6:00 pm on Thursday, November 14, 20
'"/>

Contact: Tierney Saccavino, Acorda
tsaccavino@acorda.com
914-347-4300
Porter Novelli
13-Nov-2002


Page: 1 2

Related biology news :

1. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
2. Acorda Therapeutics acquires CeNeS neuregulin products
3. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
4. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
5. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
7. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
8. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
9. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
10. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
11. Immerge BioTherapeutics announces identification of PERV receptor

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2020)... ... February 05, 2020 , ... ... greater ease, efficiency and insight to sample processing within laboratories. , Built ... laboratories conducting research in various fields, LabKey Sample Manager has been designed with ...
(Date:1/29/2020)... ... January 29, 2020 , ... ... new Analytics and Data Sciences practice, providing consulting services for strategy, research and ... announced by Mike Townley, co-founder and Managing Partner of CREO, an innovative management ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... companies and government agencies, announced that the firm has established a presence in ... Cambridge office will be in the Cambridge Innovation Center (CIC), at One Broadway ...
Breaking Biology News(10 mins):
(Date:2/19/2020)... Pa. (PRWEB) , ... February 19, 2020 , ... ... and process solutions for the life sciences industry, today announced the opening of ... Kenji Nagamura, Associate Partner, Red Nucleus R&D. , Red Nucleus announced the new ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... in North America, today announced that the City of Fort Worth has partnered ... management needs. Commencing in April of 2020, Synagro will assume operation of the ...
(Date:2/5/2020)... BEACH, Fla. (PRWEB) , ... February 05, 2020 , ... ... an annual observance, sponsored by The National Organization for Rare Disorders (NORD), to raise ... patients’ lives ( rarediseaseday.org ). The Balancing Act’s “Behind The Mystery” rare ...
(Date:1/28/2020)... ... 28, 2020 , ... Lifecycle Biotechnologies announced today ... manufactures within North America. Both Lifecycle and Midland have supported this industry for ... to pool their collective resources and provide the industry with support, service, and ...
Breaking Biology Technology:
Cached News: